Arsenic Speciation in Urine from Acute Promyelocytic Leukemia Patients undergoing Arsenic Trioxide Treatment

Chemical Research in Toxicology

Volumn 17, Issue 1, 2004, Pages 95-103

  Wang, Zhongwen ^a   Zhou, Jin ^b   Lu, Xiufen ^a   Gong, Zhilong ^a   Le, X Chris ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; ARSONIC ACID DERIVATIVE; CACODYLIC ACID; DIETHYLDITHIOCARBAMIC ACID; DIMETHYLARSINOUS ACID; DRUG METABOLITE; METHANEARSONIC ACID; MONOMETHYLARSONOUS ACID; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BILIARY EXCRETION; CASE REPORT; CHINA; DOSE RESPONSE; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; HUMAN; LOW DRUG DOSE; MALE; METHYLATION; PROMYELOCYTIC LEUKEMIA; URINALYSIS;

ADULT; ANTINEOPLASTIC AGENTS; ARSENIC; ARSENICALS; ARSENITES; CACODYLIC ACID; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; INJECTIONS, INTRAVENOUS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; METHYLATION; MIDDLE AGED; OXIDATION-REDUCTION; OXIDES;

EID: 1642498275     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx0341714     Document Type: Article

References (58)

1. Sun, H. D., Ma, L., Hu, X. C., and Zhang, T. D. (1992) Ai-ling 1 treated 32 cases of acute promyelocytic leukemia. Chin. J. Integr. Chin. West Med. 12, 170-171.
2. Zhang, P., Wang, S. Y., Hu, L. H., Shi, F. D., Qiu, F. Q., Hong, G. J., Han, X. Y., Yang, H. F., Sun, Y. Z., Liu, Y. P., Zhao, J., and Jin, Z. J. (1996) Treatment of 72 cases of acute promyelocytic leukemia with intravenous arsenic trioxide. Chin. J. Hematol. 17, 58-62.
3. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89, 3354-3360.
4. Soignet, S. L., Maslak, P., Wang, Z. G., Jhanwar, S., Calleja, E., Dardashti, L. J., Corso, D., Deblasio, A., Gabrilove, J., Scheinberg, D. A., Pandolfi, P. P., and Warrell, R. P. J. J. (1998) Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N. Engl. J. Med. 339, 1341-1348.
5. Niu, C., Yan, H., Yu, T., Sun, H. P., Liu, J. X., Li, X. S., Wu, W., Zhang, F. Q., Chen, Y., Zhou, L., Li, J. M., Zeng, X. Y., Ou Yang, R. R., Yuan, M. M., Ren, M. Y., Gu, F. Y., Cao, Q., Gu, B. W., Su, X. Y., Chen, G. Q., Xiong, S. M., Zhang, T. D., Waxam, S., Wang, Z. Y., Chen, Z., Hu, J., Shen, Z. X., and Chen, S. J. (1999) Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic patients. Blood 94, 3315-3324.
6. Soignet, S., Frankel, S., Tallman, M., Kantarjian, H., Calleja, E., Stone, R. M., Kalaycio, M., Scheinberg, D. A., Steinherz, P., Sievers, E. L., Coutre, S., Dahlberg, S., Ellison, R., and Warrell, R. P., Jr. (2001) United States multicenter trial of arsenic trioxide in relapsed acute promyelocytic leukemia. J. Clin. Oncol. 19, 3852-3860.
7. Lu, D.-P., Qiu, J.-Y., Jiang, B., Wang, Q., Liu, K.-Y., Liu, Y.-R., and Chen, S.-S. (2002) Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report. Blood 99, 3136-3143.
8. Zhu, J., Chen, Z., Lallemand-Breitenbach, V., and de The, H. (2002) How acute promyelocytic leukemia revived arsenic. Nat. Rev. Cancer 2, 1-9.
9. Westervelt, P., Brown, R. A., Adkins, D. R., Khoury, H., Curtin, P., Hurd, D., Luger, S. M., Ma, M. K., Ley, T. J., and DiPersio, J. F. (2001) Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood 98, 266-271.
10. 3 exerts dose-dependent dual effects on APL cells. Blood 89, 3345-3353.
11. Wang, Z. G., Rivi, R., Delva, L., Konig, A., Scheinberg, D. A., Gambacorti-Passerini, C., Gabrilove, J. L., Warrell, R. P., and Pandolfi, P. P. (1998) Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RAR α independent manner. Blood 92, 1497-1504.
12. Jing, Y. K., Dai, J., Chalmers-Redman, R. M. E., Tatton, W. G., and Waxman, S. (1999) Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 94, 2102-2111.
13. Zhu, J., Koken, M. H. M., Quignon, F., ChelbiAlix, M. K., Degos, L., Wang, Z. Y., Chen, Z., and deThe, H. (1997) Arsenic induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc. Natl. Acad. Sci. U.S.A. 96, 14807-14812.
14. Lallemand-Breitenbach, V., Guillemin, M.-C., Janin, A., Daniel, M.-T., Degos, L., Kogan, S. C., Bishop, J. M., and de Thé, H. (1999) Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J. Exp. Med. 189, 1043-1052.
15. El-Sabban, M. E., Nasr, R., Dbaibo, G., Hermine, O., Abboushi, N., Quignon, F., Ameisen, J. C., Bex, F., de Thé, H., and Bazarbachi, A. (2000) Arsenic-interferon-α-triggered apoptosis in HTLV-1 transformed cells is associated with Tax down-regulation and reversal of NF-kB activation. Blood 96, 2849-2855.
16. Zhu, Q., Zhang, J. W., Zhu, H. Q., Shen, Y. L., Flexor, M., Jia, P. M., Yu, Y., Cai, X., Waxman, S., Lanotte, M., Chen, S. J., Chen, Z., and Tong, J. H. (2002) Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends and a novel signaling cross-talk. Blood 99, 1014-1022.
17. Buchet, J. P., and Lauwerys, R. (1994) Inorganic arsenic metabolism in humans. In Arsenic Exposure and Health (Chappell, W. R., Abernathy, C. O., and Cothern, C. R., Eds.) pp 181-189, Science and Technology Letters, Northwood, U.K.
18. Aposhian, H. V. (1997) Enzymatic methylation of arsenic species and other new approaches to arsenic toxicity. Annu. Rev. Pharmacol. Toxicol. 37, 397-419.
19. Cullen, W. R., and Reimer, K. J. (1989) Arsenic speciation in the environment. Chem. Rev. 89, 713-764.
20. Thomas, D. J., Styblo, M., and Lin, S. (2001) The cellular metabolism and systemic toxicity of arsenic. Toxicol. Appl. Pharmacol. 176, 127-144.
21. Vahter, M. (2002) Mechanisms of arsenic biotransformation. Toxicology 181-182, 211-217.
22. Le, X. C. (2001) Arsenic speciation in the environment and humans. In Environmental Chemistry of Arsenic (Frankenberger, W. T., Jr., Ed.) pp 95-116, Marcel Dekker, New York.
23. Aposhian, H. V., Zheng, B., Aposhian, M. M., Le, X. C., Cebrian, M. E., Cullen, W., Zakharyan, R. A., Ma, M., Dart, R. C., Cheng, Z., Andrewes, P., Yip, L., O'Malley, G. F., Maiorino, R. M., Voorhies, W. V., Healy, S. M., and Titcomb, A. (2000) DMPS-arsenic challenge test II. Modulation of arsenic species, including monomethylarsonous acid, excreted in human urine. Toxicol. Appl. Pharmacol. 165, 74-83.
24. III) in urine of humans exposed to inorganic arsenic. Chem. Res. Toxicol. 13, 693-697.
25. Le, X. C., Lu, X. F., Ma, M. S., Cullen, W. R., Aposhian, H. V., and Zheng, B. S. (2000) Speciation of Key arsenic metabolic intermediates in human urine. Anal. Chem. 72, 5172-5177.
26. Le, X. C., Ma, M., Lu, X., Cullen, W. R., Aposhian, H. V., and Zheng, B. (2000) Determination of monomethylarsonous acid, a key arsenic methylation intermediate, in human urine. Environ. Health Perspect. 108, 1015-1018.
27. Del Razo, L. M., Styblo, M., Cullen, W. R., and Thomas, D. J. (2001) Determination of trivalent methylated arsenicals in biological matrices. Toxicol. Appl. Pharmacol. 174, 282-293.
28. Mandal, B. K., Ogra, Y., and Suzuki, K. T. (2001) Identification of dimethylarsinous and monomethylarsonous acids in human urine of the arsenic-affected areas in West Bengal, India. Chem. Res. Toxicol. 14, 371-378.
29. Gong, Z., Jiang, G., Cullen, W. R., Aposhian, H. V., and Le, X. C. (2002) Determination of arsenic metabolic complex excreted in human urine after administration of sodium 2,3-dimercapto-1-propane sulfonate. Chem. Res. Toxicol. 15, 1318-1323.
30. Sampayo-Reyes, A., Zakharyan, R. A., Healy, S. M., and Aposhian, H. V. (2000) Monomethylarsonic acid reductase and monomethylarsonous acid in hamster tissue. Chem. Res. Toxicol. 13, 1181-1186.
31. Styblo, M., Serves, S. V., Cullen, W. R., and Thomas, D. J. (1997) Comparative inhibition of yeast glutathione reductase by arsenicals and arsenothiols. Chem. Res. Toxicol. 10, 27-33.
32. Lin, S., Cullen, W. R., and Thomas, D. J. (1999) Methylarsenicals and arsinothiols are potent inhibitors of mouse liver thioredoxin reductase. Chem. Res. Toxicol. 12, 924-930.
33. III) is more toxic than arsenite in Chang human hepatocytes. Toxicol. Appl. Pharmacol. 163, 203-207.
34. 50 in hamsters and in vitro inhibition of pyruvate dehydrogenase. Chem. Res. Toxicol. 14, 651-656.
35. Mass, M. J., Tennant, A., Roop, R. C., Cullen, W. R., Styblo, M., Thomas, D. J., and Kligerman, A. D. (2001) Methylated trivalent arsenic species are genotoxic. Chem. Res. Toxicol. 14, 355-361.
36. Cohen, S. M., Arnold, L. L., Uzvolgyi, E., Cano, M., St. John, M., Yamamoto, S., Lu, X., and Le, X. C. (2002) Possible role of dimethylarsinous acid in dimethylarsinic acid-induced urothelial toxicity and regeneration in the rat. Chem. Res. Toxicol. 15, 1150-1157.
37. Styblo, M., Del Razo, L. M., Vega, L., Germolec, D. R., LeCluyse, E. L., Hamilton, G. A., Reed, W., Wang, C., Cullen, W. R., and Thomas, D. J. (2000) Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells. Arch. Toxicol. 74, 289-299.
38. Chen, G.-Q., Zhou, L., Styblo, M., Walton, F., Jing, Y., Weinberg, R., Chen, Z., and Waxman, S. (2003) Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells. Cancer Res. 64, 1853-1859.
39. Cullen, W. R., McBride, B. C., Manji, H., Pickett, A. W., and Reglinski, J. (1989) The metabolism of methylarsine oxide and sulfide. Appl. Organomet. Chem. 3, 71-78.
40. Burrows, G. J., and Turner, E. E. (1920) A new type of compound containing arsenic. J. Chem. Soc. Trans. 117, 1373-1383.
41. Le, X. C., and Ma, M. (1998) Short-column liquid chromatography with hydride generation atomic fluorescence detection for the speciation of arsenic. Anal. Chem. 70, 1926-1933.
42. Ma, M., and Le, X. C. (1998) Effect of arsenosugar ingestion on urinary arsenic speciation. Clin. Chem. 44, 539-550.
43. Feldmann, J., Lai, V. W. M., Cullen, W. R., Ma, M., Lu, X., and Le, X. C. (1999) Sample preparation and storage can change arsenic speciation in human urine. Clin. Chem. 45, 1988-1997.
44. Jiang, G., Gong, Z., Li, X.-F., Cullen, W. R., and Le, X. C. (2003) Interaction of trivalent arsenicals with metallothionein. Chem. Res. Toxicol. 16, 873-880.
45. Gong, Z. L., Lu, X. F., Cullen, W. R., and Le, X. C. (2001) Unstable trivalent arsenic metabolites, monomethylarsonous acid and dimethylarsinous acid. J. Anal. At. Spectrom. 16, 1409-1413.
46. Kitchin, K. T. (2001) Recent advance in arsenic carcinogenesis: models of action, animal model systems, and methylated arsenic metabolites. Toxicol. Appl. Pharmacol. 172, 249-261.
47. Whelton, A., Watson, A. J., and Rock, R. C. (1986) Nitrogen metabolites and renal function. In Clinical Chemistry, 2nd ed. (Burtis, C. A., and Ashwood, E. R., Eds.) p 1535, W. B. Sanders, Philadelphia, PA.
48. Buchet, J. P., Lauwerys, R., and Roels, H. (1981) Urinary excretion of inorganic arsenic and its metabolites after repeated injgestion of sodium metaarsenite by volunteers. Int. Arch. Occup. Environ. Health 48, 111-118.
49. Buchet, J. P., Lauwerys, R., and Roels, H. (1981) Comparison of the urinary excretion of arsenic metabolites after a single oral dose of sodium arsenite, monomethylarsonate, or dimethylarsinate in man. Int. Arch. Occup. Environ. Health 48, 71-79.
50. Offergelt, J. A., Roels, H., Buchet, J. P., Boeckx, M., and Lauwerys, R. (1992) Relation between airborne arsenic trioxide and urinary excretion of inorganic arsenic and its methyated metabolites. Br. J. Ind. Med. 49, 387-393.
51. NRC (National Research Council) (1999) Arsenic in Drinking Water, National Academy Press, Washington, DC.
52. Buchet, J. P., and Lauwerys, R. (1988) Role of thiols in the in vitro methylation of inorganic arsenic by rat liver cytosol. Biochem. Pharmacol. 37, 3149-3153.
53. Styblo, M., Delnomdedieu, M., and Thomas, D. J. (1996) Mono- and di-methylation of arsenic in rat liver cytosol in vitro. Chem.-Biol. Interact. 99, 147-164.
54. Challenger, F. (1945) Biological methylation. Chem. Rev. 36, 315-361.
55. Styblo, M., Drobna, Z., Jaspers, I., Lin, S., and Thomas, D. J. (2002) The role of biomethylation in toxicity and carcinogenicity of arsenic: a research update. Environ. Health Perspect. 110 (Suppl. 5), 767-771.
56. Del Razo, L. M., Garcia-Vargas, G. G., Vargas, H., Albores, A., Gonsebatt, M. E., Montero, R., Ostrosky-Wegman, P., Kelsh, M., and Cebrian, M. E. (1997) Altered profile of urinary arsenic metabolites in adults with chronic arsenicism. Arch. Toxicol. 71, 211-217.
57. Hopenhayn-Rich, C., Biggs, M. L., Smith, A. H., Kalman, D., and Moore, L. E. (1996) Methlyation study in a population environmentally exposed to high arsenic water. Environ. Health Perspect. 104, 620-628.
58. Hopenhayn-Rich, C., Smith, A. H., and Goeden, H. M. (1993) Human studies do not support the methylation threshold hypothesis for the toxicity of inorganic arsenic. Environ. Res. 60, 161-177.